Compare Hims and Hers Health Inc (HIMS) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Otis Worldwide Corp — how do they compare? Hims and Hers Health Inc trades at $29.47 (market cap $6.55B), while Otis Worldwide Corp trades at $65.92 (market cap $25.17B). The key difference: Otis Worldwide Corp is far larger — about 3.8× Hims and Hers Health Inc's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Otis Worldwide Corp for 65 Days on average.
| HIMS | OTIS | |
|---|---|---|
Market Cap | $6.55B | $25.17B |
Volume | 14,842,814 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $62.76 | $93.62 |
52-Week Low | $14.52 | $64.05 |
Typical Hold Time | 21 Days | 65 Days |
Enterprise Value | $7.25B | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
Otis Worldwide trades at $65.74, down 1.07% with a bearish technical signal and recent earnings misses. The stock trades near its 52-week low with mixed analyst sentiment (46.7% buy, 46.7% hold) despite a consensus price target of $87.00. Revenue growth remains stable at $14.43B (2025) with 10.17% net margins, though service margins face pressure from labor costs. Recent CEO succession news and China project wins provide strategic context amid weak equipment demand.
The outlook balances stable service revenue against margin pressures and China exposure. Upside exists if service margins recover and modernization backlog converts, but near-term headwinds and technical weakness suggest cautious positioning. Key risks include prolonged China weakness and execution on cost controls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
